Literature DB >> 2447193

Purification and characterization of calpains from pig epidermis and their action on epidermal keratin.

Y Ando1, Y Miyachi, S Imamura, R Kannagi, T Murachi.   

Abstract

Two forms of Ca++-dependent cysteine proteinases, calpain I, requiring low Ca++ (microM concentration), and calpain II, requiring high Ca++ (mM concentration), were purified from the cytosolic fraction of pig epidermis. Calpains I and II were separated on DEAE-cellulose chromatography, and thereafter they were purified by separate but almost identical procedures, which included chromatographies on Sephacryl S-300, Blue Sepharose CL-6B, and DEAE Bio-Gel A. Purified calpains I and II required 10 and 450 microM Ca++ for half-maximal activation, respectively, and had an optimal pH of 7.0 to 8.0. Both enzymes were heterodimers and composed of one heavy subunit (83 kDa for calpain I and 80 kDa for calpain II) and one light subunit (29 kDa for both enzymes). The action of calpains I and II on keratin extracted from the same tissue was studied. Both enzymes rapidly cleaved keratin into small fragments. The cleavage depends on Ca++ and could be blocked by leupeptin and calpastation, an endogenous calpain-specific inhibitor, which was also found in the cytosolic fraction of pig epidermis and partially purified.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447193     DOI: 10.1111/1523-1747.ep12462532

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  Human epidermis contains coagulation factor XIII.

Authors:  Y Ando; S Imamura; R Kannagi
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Calpain activates two transglutaminases from porcine skin.

Authors:  Y Ando; S Imamura; T Murachi; R Kannagi
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

3.  Cytokeratins mediate epithelial innate defense through their antimicrobial properties.

Authors:  Connie Tam; James J Mun; David J Evans; Suzanne M J Fleiszig
Journal:  J Clin Invest       Date:  2012-09-24       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.